MedPath

FDA Approves Abionic's CAPSULE PSP for Rapid Sepsis Detection

• Abionic's CAPSULE PSP, a point-of-care diagnostic, has received FDA approval for early sepsis detection, enabling quicker clinical decision-making. • The device measures Pancreatic Stone Protein (PSP) levels, a biomarker that rises rapidly in response to bacterial infections leading to sepsis. • CAPSULE PSP provides results in approximately 5 minutes using a small blood sample, facilitating timely intervention and improved patient outcomes.

Abionic has announced that its CAPSULE PSP has received FDA approval for the rapid detection of sepsis. The device is a point-of-care diagnostic tool designed to measure Pancreatic Stone Protein (PSP), a biomarker that increases significantly in the early stages of sepsis.

Significance of Early Sepsis Detection

Sepsis is a life-threatening condition that arises when the body's response to an infection spirals out of control, leading to tissue damage, organ failure, and death. Early diagnosis and treatment are critical to improving patient outcomes. The CAPSULE PSP offers a significant advancement in this area by providing rapid results that can guide clinical decision-making.

How CAPSULE PSP Works

The CAPSULE PSP utilizes a small blood sample to measure PSP levels, delivering results in approximately 5 minutes. PSP is known to elevate rapidly in response to bacterial infections, making it a reliable early indicator of sepsis. This quick turnaround time enables healthcare providers to initiate appropriate treatment sooner, potentially saving lives and reducing the severity of the condition.

Clinical Impact

With the FDA's approval, the CAPSULE PSP is poised to make a substantial impact on sepsis management in healthcare settings. Its ease of use and rapid results can help clinicians quickly identify patients at risk, allowing for timely interventions such as antibiotic administration and supportive care. This advancement addresses a critical unmet need in the fight against sepsis, offering hope for improved patient outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Biomea Fusion Announces Topline Results from Phase II COVALENT-111 Trial

Biomea Fusion is set to release topline results from its Phase II COVALENT-111 clinical trial, which evaluates a novel covalent menin inhibitor.
The trial focuses on patients with relapsed or refractory acute myeloid leukemia (AML), a challenging-to-treat blood cancer.

Puma Biotechnology Initiates Phase II Trial of Alisertib in HR+/HER2- Breast Cancer

Puma Biotechnology has commenced the ALISCA™-Breast1 Phase II trial to evaluate alisertib in hormone receptor-positive, HER2-negative advanced breast cancer.
The trial will assess the efficacy and safety of alisertib in patients who have progressed on prior CDK4/6 inhibitor therapy.

FDA Approves Abionic's CAPSULE PSP for Early Sepsis Detection; Fapon to Commercialize in China

Abionic's CAPSULE PSP, an early sepsis detection test, has received FDA 510(k) clearance, marking a significant advancement in sepsis diagnosis.
The test utilizes Pancreatic Stone Protein (PSP) as a biomarker, detecting sepsis 24-48 hours earlier than current standard methods, improving patient outcomes.

Abionic's CAPSULE PSP Receives FDA Approval for Early Sepsis Detection

Abionic's CAPSULE PSP, an innovative test for early sepsis detection, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The CAPSULE PSP test measures Pancreatic Stone Protein (PSP), a biomarker that rises in response to infections and inflammation, enabling earlier sepsis detection.

FDA Approves Abionic's CAPSULE PSP for Early Sepsis Detection

Abionic's CAPSULE PSP, an innovative in vitro diagnostic test for early sepsis detection, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
The CAPSULE PSP test measures Pancreatic Stone Protein (PSP) levels, an emerging biomarker that can detect sepsis 24-48 hours earlier than current standard methods.

Celldex's Barzolvolimab Meets All Primary and Secondary Endpoints in Clinical Trial

Celldex Therapeutics announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a recent clinical trial.
Barzolvolimab is a novel monoclonal antibody designed to bind to and inhibit the KIT receptor, potentially treating various mast cell-driven diseases.

CytoMed Therapeutics Initiates Phase I Trial of CTM-ONC in Solid Tumors

CytoMed Therapeutics has begun its Phase I ANGELICA trial, evaluating CTM-ONC in patients with advanced solid tumors.
The trial utilizes CytoMed's patented donor-derived allogeneic cell therapy platform to enhance safety and efficacy.

Ionis Pharmaceuticals' ION582 Receives FDA Fast Track Designation for Angelman Syndrome Treatment

ION582, developed by Ionis Pharmaceuticals, has been granted Fast Track designation by the FDA for treating Angelman syndrome.
This designation aims to expedite the development and review of ION582, addressing an unmet need for Angelman syndrome patients.

Abionic's IVD CAPSULE PSP Receives FDA Clearance for Early Sepsis Detection

Abionic's IVD CAPSULE PSP test has been granted FDA 510(k) clearance, marking a significant advancement in the rapid detection of sepsis in the U.S.
The IVD CAPSULE PSP measures Pancreatic Stone Protein (PSP) levels, enabling earlier sepsis detection than current methods by 24-48 hours.

FDA Grants Rare Pediatric Disease Designation to Modalis Therapeutics' MDL-101 for Genetic Disorder Treatment

Modalis Therapeutics receives Rare Pediatric Disease Designation from the FDA for MDL-101, targeting a severe genetic disorder.
MDL-101 is designed to address the underlying genetic cause of the disease, offering a potential new treatment avenue.

Reference News

[1]
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis
galvnews.com · Oct 31, 2024

A form includes a dropdown for selecting a state/province and a text field for entering a zip code, both required. Anoth...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy